Mechanisms underlying platelet function defect in a pedigree with familial platelet disorder with a predisposition to acute myelogenous leukemia: Potential role for candidate RUNX1 targets

Journal of Thrombosis and Haemostasis

Volumn 12, Issue 5, 2014, Pages 761-772

  Glembotsky, A C ^a   Bluteau, D ^b,c   Espasandin, Y R ^a   Goette, N P ^a   Marta, R F ^a   Marin Oyarzun, C P ^a   Korin, L ^a   Lev, P R ^a   Laguens, R P ^d   Molinas, F C ^a   Raslova, H ^b   Heller, P G ^a  

^a INSTITUTO DE INVESTIGACIONES MÉDICAS ALFREDO LANARI   (Argentina)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c PSL RESEARCH UNIVERSITY   (France)

^d FAVALORO UNIVERSITY   (Argentina)

Author keywords

Blood platelet disorder; FPD AML; NF E2 transcription factor; Platelet function tests; Rab27B protein, human; RUNX1 protein

Indexed keywords

INTEGRIN; MYOSIN LIGHT CHAIN; MYOSIN LIGHT CHAIN 9; PADGEM PROTEIN; RNA; THROMBOSPONDIN 1; TRANSCRIPTION FACTOR NF E2 P45 SUBUNIT; TRANSCRIPTION FACTOR RUNX1; UNCLASSIFIED DRUG; ADENOSINE TRIPHOSPHATE; BETA3 INTEGRIN; GLYCOPROTEIN IIB; NFE2 PROTEIN, HUMAN; RUNX1 PROTEIN, HUMAN; TYROSINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; CASE REPORT; CELL LYSATE; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DISEASE PREDISPOSITION; ELECTRON MICROSCOPY; FAMILIAL DISEASE; FAMILIAL PLATELET DISORDER; FEMALE; GENE CONTROL; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; LIGHT; LUCIFERASE ASSAY; MALE; MEGAKARYOCYTE; MIDDLE AGED; MUTANT; PEDIGREE; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; STORAGE; THROMBOCYTE AGGREGATION; THROMBOCYTE DYSFUNCTION; THROMBOCYTE STRUCTURE; WILD TYPE; YOUNG ADULT; BLOOD; BLOOD CLOTTING PARAMETERS; COMPLICATION; CYTOLOGY; FAMILY HEALTH; GENE EXPRESSION PROFILING; METABOLISM; PHOSPHORYLATION; THROMBOCYTE; THROMBOCYTE DISORDER;

ADENOSINE TRIPHOSPHATE; ADULT; BLOOD PLATELET DISORDERS; BLOOD PLATELETS; CORE BINDING FACTOR ALPHA 2 SUBUNIT; FAMILY HEALTH; FEMALE; GENE EXPRESSION PROFILING; HUMANS; INTEGRIN BETA3; LEUKEMIA, MYELOID, ACUTE; MALE; NF-E2 TRANSCRIPTION FACTOR, P45 SUBUNIT; PEDIGREE; PHENOTYPE; PHOSPHORYLATION; PLATELET AGGREGATION; PLATELET FUNCTION TESTS; PLATELET MEMBRANE GLYCOPROTEIN IIB; SIGNAL TRANSDUCTION; TYROSINE; YOUNG ADULT;

EID: 84901196941     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12550     Document Type: Article

References (41)

1. Song WJ, Sullivan MG, Legare RD, Hutchings S, Tan X, Kufrin D, Ratajczak J, Resende IC, Haworth C, Hock R, Loh M, Felix C, Roy DC, Busque L, Kurnit D, Willman C, Gewirtz AM, Speck NA, Bushweller JH, Li FP. Haploinsufficiency of CBFA2 causes familial platelet disorder with propensity to develop acute myelogenous leukaemia. Nat Genet 1999; 23: 166-75.
2. Owen CJ, Toze CL, Koochin A, Forrest DL, Smith CA, Stevens JM, Jackson SC, Poon MC, Sinclair GD, Leber B, Johnson PR, Macheta A, Yin JA, Barnett MJ, Lister TA, Fitzgibbon J. Five new pedigrees with inherited RUNX1 mutations causing familial platelet disorder with propensity to myeloid malignancy. Blood 2008; 112: 4639-45.
3. Stockley J, Morgan NV, Bem D, Lowe GC, Lordkipanidzé M, Dawood B, Simpson MA, Macfarlane K, Horner K, Leo VC, Talks K, Motwani J, Wilde JT, Collins PW, Makris M, Watson SP, Daly ME. Enrichment of FLI1 and RUNX1 mutations in families with excessive bleeding and platelet dense granule secretion defects. Blood 2013; 122: 4090-3.
4. Gerrard JM, Israels ED, Bishop AJ, Schroeder ML, Beattie LL, McNicol A, Israels SJ, Walz D, Greenberg AH, Ray M, Israels LG. Inherited platelet-storage pool deficiency associated with a high incidence of acute myeloid leukaemia. Br J Haematol 1991; 79: 246-55.
5. Béri-Dexheimer M, Latger-Cannard V, Philippe C, Bonnet C, Chambon P, Roth V, Grégoire MJ, Bordigoni P, Lecompte T, Leheup B, Jonveaux P. Clinical phenotype of germline RUNX1 haploinsufficiency: from point mutations to large genomic deletions. Eur J Hum Genet 2008; 16: 1014-18.
6. Buijs A, Poddighe P, van Wijk R, van Solinge W, Borst E, Verdonck L, Hagenbeek A, Pearson P, Lokhorst H. A novel CBFA2 single-nucleotide mutation in familial platelet disorder with propensity to develop myeloid malignancies. Blood 2001; 98: 2856-8.
7. Latger-Cannard V, Philippe C, Jonveaux P, Lecompte T, Favier R. Dysmegakaryopoiesis, a clue for an early diagnosis of familial platelet disorder with propensity to acute myeloid leukemia in case of unexplained inherited thrombocytopenia associated with normal-sized platelets. J Pediatr Hematol Oncol 2011; 33: e264-6.
8. Gabbeta J, Yang X, Sun L, McLane MA, Niewiarowski S, Rao AK. Abnormal inside-out signal transduction-dependent activation of glycoprotein IIb-IIIa in a patient with impaired pleckstrin phosphorylation. Blood 1996; 87: 1368-76.
9. Kurokawa M. AML1/Runx1 as a versatile regulator of hematopoiesis: regulation of its function and a role in adult hematopoiesis. Int J Hematol 2006; 84: 136-42.
10. Bluteau D, Glembotsky AC, Raimbault A, Balayn N, Gilles L, Rameau P, Nurden P, Alessi MC, Debili N, Vainchenker W, Heller PG, Favier R, Raslova H. Dysmegakaryopoiesis of FPD/AML pedigrees with constitutional RUNX1 mutations is linked to myosin II deregulated expression. Blood 2012; 120: 2708-18.
11. Heller PG, Glembotsky AC, Gandhi MJ, Cummings CL, Pirola CJ, Marta RF, Kornblihtt LI, Drachman JG, Molinas FC. Low Mpl receptor expression in a pedigree with familial platelet disorder with predisposition to acute myelogenous leukemia and a novel AML1 mutation. Blood 2005; 105: 4664-70.
12. Sun L, Gorospe JR, Hoffman EP, Rao AK. Decreased platelet expression of myosin regulatory light chain polypeptide (MYL9) and other genes with platelet dysfunction and CBFA2/RUNX1 mutation: insights from platelet expression profiling. J Thromb Haemost 2007; 5: 146-54.
13. Sun L, Mao G, Rao AK. Association of CBFA2 mutation with decreased platelet PKC-theta and impaired receptor-mediated activation of GPIIb-IIIa and pleckstrin phosphorylation: proteins regulated by CBFA2 play a role in GPIIb-IIIa activation. Blood 2004; 103: 948-54.
14. Jalagadugula G, Mao G, Kaur G, Dhanasekaran DN, Rao AK. Platelet protein kinase C-theta deficiency with human RUNX1 mutation: PRKCQ is a transcriptional target of RUNX1. Arterioscler Thromb Vasc Biol 2011; 31: 921-7.
15. Jalagadugula G, Mao G, Kaur G, Goldfinger LE, Dhanasekaran DN, Rao AK. Regulation of platelet myosin light chain (MYL9) by RUNX1: implications for thrombocytopenia and platelet dysfunction in RUNX1 haplodeficiency. Blood 2010; 116: 6037-45.
16. Kaur G, Jalagadugula G, Mao G, Rao AK. RUNX1/core binding factor A2 regulates platelet 12-lipoxygenase gene (ALOX12): studies in human RUNX1 haplodeficiency. Blood 2010; 115: 3128-35.
17. Webert K, Cook RJ, Sigouin CS, Rebulla P, Heddle NM. The risk of bleeding in thrombocytopenic patients with acute myeloid leukemia. Haematologica 2006; 91: 1530-7.
18. De Candia E, Pecci A, Ciabattoni G, De Cristofaro R, Rutella S, Yao-Wu Z, Lazzareschi I, Landolfi R, Coughlin S, Balduini CL. Defective platelet responsiveness to thrombin and protease-activated receptor agonists in a novel case of gray platelet syndrome: correlation between the platelet defect and the alpha-granule content in the patient and four relatives. J Thromb Haemost 2007; 5: 551-9.
19. Glembotsky AC, Marta RF, Pecci A, De Rocco D, Gnan C, Espasandin YR, Goette NP, Negro F, Noris P, Savoia A, Balduini CL, Molinas FC, Heller PG. International collaboration as a tool for diagnosis of patients with inherited thrombocytopenia in the setting of a developing country. J Thromb Haemost 2012; 10: 1653-61.
20. Marta RF, Goette NP, Lev PR, Chazarreta CD, Pirola CJ, Molinas FC. Normal platelets possess the soluble form of IL-6 receptor. Cytokine 2005; 29: 13-17.
21. Gilles L, Guièze R, Bluteau D, Cordette-Lagarde V, Lacout C, Favier R, Larbret F, Debili N, Vainchenker W, Raslova H. P19INK4D links endomitotic arrest and megakaryocyte maturation and is regulated by AML-1. Blood 2008; 111: 4081-91.
22. Bottega R, Pecci A, De Candia E, Pujol-Moix N, Heller PG, Noris P, De Rocco D, Podda GM, Glembotsky AC, Cattaneo M, Balduini CL, Savoia A. Correlation between platelet phenotype and NBEAL2 genotype in patients with congenital thrombocytopenia and α-granule deficiency. Haematologica 2013; 98: 868-74.
23. Fujita R, Takayama-Tsujimoto M, Satoh H, Gutiérrez L, Aburatani H, Fujii S, Sarai A, Bresnick EH, Yamamoto M, Motohashi H. NF-E2 p45 is important for establishing normal function of platelets. Mol Cell Biol 2013; 33: 2659-70.
24. Shiraga M, Ritchie A, Aidoudi S, Baron V, Wilcox D, White G, Ybarrondo B, Murphy G, Leavitt A, Shattil S. Primary megakaryocytes reveal a role for transcription factor NF-E2 in integrin alpha IIb beta 3 signaling. J Cell Biol 1999; 147: 1419-30.
25. Shivdasani RA, Rosenblatt MF, Zucker-Franklin D, Jackson CW, Hunt P, Saris CJ, Orkin SH. Transcription factor NF-E2 is required for platelet formation independent of the actions of thrombopoietin/MGDF in megakaryocyte development. Cell 1995; 81: 695-704.
26. Moroni E, Mastrangelo T, Razzini R, Cairns L, Moi P, Ottolenghi S, Giglioni B. Regulation of mouse p45 NF-E2 transcription by an erythroid-specific GATA-dependent intronic alternative promoter. J Biol Chem 2000; 275: 10567-76.
27. Tiwari S, Italiano JE, Barra DE, Mules EH, Novak EK, Swank RT, Seabra MC, Shivdasani RA. A role for Rab27b in NF-E2-dependent pathways of platelet formation. Blood 2003; 102: 3970-9.
28. Tolmachova T, Abrink M, Futter CE, Authi KS, Seabra MC. Rab27b regulates number and secretion of platelet dense granules. Proc Natl Acad Sci USA 2007; 104: 5872-7.
29. Eto K, Murphy R, Kerrigan SW, Bertoni A, Stuhlmann H, Nakano T, Leavitt AD, Shattil SJ. Megakaryocytes derived from embryonic stem cells implicate CalDAG-GEFI in integrin signaling. Proc Natl Acad Sci USA 2002; 99: 12819-24.
30. Crittenden JR, Bergmeier W, Zhang Y, Piffath CL, Liang Y, Wagner DD, Housman DE, Graybiel AM. CalDAG-GEFI integrates signaling for platelet aggregation and thrombus formation. Nat Med 2004; 10: 982-6.
31. Kerrigan SW, Gaur M, Murphy RP, Shattil SJ, Leavitt AD. Caspase-12: a developmental link between G-protein-coupled receptors and integrin alphaIIbbeta3 activation. Blood 2004; 104: 1327-34.
32. Jordan PA, Stevens JM, Hubbard GP, Barrett NE, Sage T, Authi KS, Gibbins JM. A role for the thiol isomerase protein ERP5 in platelet function. Blood 2005; 105: 1500-7.
33. Marinescu VD, Kohane IS, Riva A. MAPPER: a search engine for the computational identification of putative transcription factor binding sites in multiple genomes. BMC Bioinformatics 2005; 6: 79.
34. Wang W, Schwemmers S, Hexner EO, Pahl HL. AML1 is overexpressed in patients with myeloproliferative neoplasms and mediates JAK2V617F-independent overexpression of NF-E2. Blood 2010; 116: 254-66.
35. Lages B, Shattil SJ, Bainton DF, Weiss HJ. Decreased content and surface expression of alpha-granule membrane protein GMP-140 in one of two types of platelet alpha delta storage pool deficiency. J Clin Invest 1991; 87: 919-29.
36. Michaud J, Wu F, Osato M, Cottles GM, Yanagida M, Asou N, Shigesada K, Ito Y, Benson KF, Raskind WH, Rossier C, Antonarakis SE, Israels S, McNicol A, Weiss H, Horwitz M, Scott HS. In vitro analyses of known and novel RUNX1/AML1 mutations in dominant familial platelet disorder with predisposition to acute myelogenous leukemia: implications for mechanisms of pathogenesis. Blood 2002; 99: 1364-72.
37. Pencovich N, Jaschek R, Dicken J, Amit A, Lotem J, Tanay A, Groner Y. Cell-autonomous function of Runx1 transcriptionally regulates mouse megakaryocytic maturation. PLoS ONE 2013; 8: e64248.
38. Pencovich N, Jaschek R, Tanay A, Groner Y. Dynamic combinatorial interactions of RUNX1 and cooperating partners regulates megakaryocytic differentiation in cell line models. Blood 2011; 117: e1-14.
39. Nagy B Jr, Bhavaraju K, Getz T, Bynagari YS, Kim S, Kunapuli SP. Impaired activation of platelets lacking protein kinase C-{theta} isoform. Blood 2009; 113: 2557-67.
40. Daniel JL, Molish IR, Rigmaiden M, Stewart G. Evidence for a role of myosin phosphorylation in the initiation of the platelet shape change response. J Biol Chem 1984; 259: 9826-31.
41. Léon C, Eckly A, Hechler B, Aleil B, Freund M, Ravanat C, Jourdain M, Nonne C, Weber J, Tiedt R, Gratacap MP, Severin S, Cazenave JP, Lanza F, Skoda R, Gachet C. Megakaryocyte-restricted MYH9 inactivation dramatically affects hemostasis while preserving platelet aggregation and secretion. Blood 2007; 110: 3183-91.